Sangamo BioSciences, Inc. has signed a collaborative research agreement with Procter & Gamble Pharmaceuticals.
Under the terms of the agreement, Sangamo will provide specific Universal GeneTools to P&G Pharmaceuticals for use in their internal research and validation programs.
Financial terms were not disclosed.
“Sangamo is pleased to provide P&G Pharmaceuticals with our engineered transcription factors for their internal research and drug discovery efforts,” said Edward Lanphier, President and CEO of Sangamo.
As the number of genes identified as potential drug targets increases, the need to rapidly and efficiently confirm their role in disease increases as well.
Zinc finger DNA binding protein (ZFP) transcription factors are designed to regulate the expression of target genes in cell- based and animal models to determine their role in a particular disease.
Sangamo has entered into Universal GeneTools agreements with 18 pharmaceutical and biotechnology companies.
These collaborators are applying Sangamo’s ZFP transcription factors to the validation of human gene targets for drug discovery.
ZFP transcription factors are being incorporated into both cell-based and animal models for this purpose.
Sangamo is a leader in the development of novel transcription factors for the regulation of gene expression.
Transcription factors are proteins that turn genes on or off in virtually all organisms by recognizing specific DNA sequences.
The Company’s Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.
By engineering ZFPs so they can selectively regulate a target gene, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function.